Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
94
Views
1
CrossRef citations to date
0
Altmetric
Clinical Trial Report

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

Sarina A Piha-Paul1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9455-1660View further author information
ORCID Icon,
Ecaterina E Dumbrava1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Binoj C Nair1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Wendy Xiong1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Li Xu1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Rosa Mostorino1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Vivek Subbiah1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Nizar Tannir2 Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Siqing Fu1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Aung Naing1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Filip Janku1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Daniel D Karp1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Shreyaskumar Patel3 Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Najat C Daw4 Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-6941-8005View further author information
ORCID Icon,
David Hong1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Funda Meric-Bernstam1 Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA;5 Department of Breast Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA;6 The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Ralph Zinner7 Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USAView further author information
 show all
Pages 3037-3049 | Published online: 07 May 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.